NAGE vs TLRY
Niagen Bioscience, Inc. and Tilray Brands, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | NAGE | TLRY |
|---|---|---|
| Revenue | $129.4M | $915.5M |
| Net income | $17.4M | $-121.4M |
| Gross margin | 64.3% | 28.4% |
| Net margin | 13.4% | −11.5% |
| Return on equity | 28.3% | −7.8% |
| Diluted EPS | $0.20 | −$1.09 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | · | · |
| Equity | $76.5M | $1.6B |
| Net debt / equity | · | −0.13× |
| Current ratio | 4.86× | 2.21× |
| Revenue CAGR 5y | 16.9% | 12.3% |
| Profit CAGR 5y | · | · |
TLRY bills 7.1× the revenue of NAGE, and TLRY closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | NAGE | TLRY |
|---|---|---|
| FY2025 | $129.4M | $915.5M |
| FY2024 | $99.6M | $821.3M |
| FY2023 | $83.6M | $788.9M |
| FY2022 | $72.0M | $627.1M |
| FY2021 | $67.4M | $628.4M |
| FY2020 | $59.3M | $513.1M |
| FY2019 | $46.3M | $405.3M |
| FY2018 | $31.6M | $179.3M |
| FY2017 | $21.2M | $20.5M |
| FY2016 | $21.7M | $12.6M |
Bottom line
| Fiscal year | NAGE | TLRY |
|---|---|---|
| FY2025 | $17.4M | $-121.4M |
| FY2024 | $8.6M | $-2.2B |
| FY2023 | $-4.9M | $-245.0M |
| FY2022 | $-16.5M | $-1.5B |
| FY2021 | $-27.1M | $-476.8M |
| FY2020 | $-19.9M | $-367.4M |
| FY2019 | $-32.1M | $-102.5M |
| FY2018 | $-33.3M | $-25.0M |
| FY2017 | $-11.4M | $-7.8M |
| FY2016 | $-2.9M | $-7.9M |
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$786,031,000 | TLRY |
| FY2024 | −$721,712,000 | TLRY |
| FY2023 | −$705,372,000 | TLRY |
| FY2022 | −$555,074,000 | TLRY |
| FY2021 | −$560,923,000 | TLRY |
| FY2020 | −$453,828,000 | TLRY |
| FY2019 | −$359,035,000 | TLRY |
| FY2018 | −$147,746,000 | TLRY |
| FY2017 | +$663,000 | NAGE |
| FY2016 | +$9,020,648 | NAGE |
The higher-revenue side has changed between NAGE and TLRY over this period. The gap has widened since the earliest year compared.
10 of 16 comparable fiscal years — a year missing data on either side is not counted.
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +24.9 pp | NAGE |
| FY2024 | +274.2 pp | NAGE |
| FY2023 | +22.3 pp | NAGE |
| FY2022 | +207.1 pp | NAGE |
| FY2021 | +28.9 pp | NAGE |
| FY2020 | +31.9 pp | NAGE |
| FY2019 | −44.6 pp | TLRY |
| FY2018 | −85.4 pp | TLRY |
| FY2017 | −15.6 pp | TLRY |
| FY2016 | +48.8 pp | NAGE |
The higher net margin has changed hands between NAGE and TLRY over this period.
10 of 16 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
TLRY's net margin has been more volatile than NAGE's over the 10 comparable fiscal years — 85.6 percentage points of standard deviation against 34.9.
10 of 16 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between NAGE and TLRY over these 10 fiscal years — NAGE led in 7 and TLRY in 3.
10 of 16 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
TLRY's return on equity has been more volatile than NAGE's over the 8 comparable fiscal years — 98.1 percentage points of standard deviation against 58.3.
8 of 16 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between NAGE and TLRY over these 8 fiscal years — NAGE led in 3 and TLRY in 5.
8 of 16 comparable fiscal years — a year missing data on either side is not counted.